Stockscreener 앱 받기
1.35
2.17%
-0.03
시간 외 거래:
1.35
전일 마감가:
$1.38
열려 있는:
$1.37
하루 거래량:
663.50K
Relative Volume:
1.43
시가총액:
$178.18M
수익:
-
순이익/손실:
$-45.44M
주가수익비율:
-3.6486
EPS:
-0.37
순현금흐름:
$-42.28M
1주 성능:
-28.95%
1개월 성능:
-27.42%
6개월 성능:
-15.62%
1년 성능:
-15.09%
1일 변동 폭
$1.27
$1.38
1주일 범위
$1.27
$1.935
52주 변동 폭
$0.765
$2.34
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
CMPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CMPX | 1.35 | 178.18M | 0 | -45.44M | -42.28M | -0.37 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-31 | 개시 | Jefferies | Buy |
| 2023-01-27 | 개시 | Stifel | Buy |
| 2022-05-23 | 재개 | H.C. Wainwright | Buy |
| 2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
| 2022-01-19 | 개시 | B. Riley Securities | Buy |
| 2021-12-22 | 개시 | Raymond James | Outperform |
| 2021-12-20 | 개시 | SVB Leerink | Outperform |
| 2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace
FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World
Compass Therapeutics (NASDAQ:CMPX) Cut to Market Perform at Leerink Partners - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update - MarketBeat
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock - MSN
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious - MSN
Leerink Partnrs Downgrades Compass Therapeutics (NASDAQ:CMPX) to Hold - MarketBeat
DelphX announces non-brokered unit private placement - MSN
U.S. STOCKS FuelCell Energy, consumer goods stocks, Rocket Companies - XM
Compass Therapeutics (NASDAQ:CMPX) Lowered to Market Perform Rating by Leerink Partners - MarketBeat
Wedbush Predicts Higher Earnings for Compass Therapeutics - MarketBeat
Research Analysts Issue Forecasts for CMPX FY2024 Earnings - MarketBeat
Janus Henderson Group PLC's Strategic Reduction in Compass Thera - GuruFocus.com
FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment - Benzinga
Research Analysts Offer Predictions for CMPX FY2028 Earnings - MarketBeat
Compass Therapeutics Reports Q3 2024 Financials and Clinical Progress - TipRanks
Compass Therapeutics to Participate in Upcoming Investor Events - The Manila Times
Compass Therapeutics (CMPX) to Present at Stifel and Jefferies Healthcare Conferences | CMPX Stock News - StockTitan
PD-1 and PD-L1 Inhibitors Market Projected to Surge, Reaching USD XX Billion by 2031 As Revealed In New Report - WhaTech
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update - GlobeNewswire
Compass Therapeutics Reports Key Trial Progress, $135M Cash Runway Through 2027 | CMPX Stock News - StockTitan
Compass Therapeutics Inc (CMPX) Quarterly 10-Q Report - Quartzy
Compass Therapeutics' (CMPX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Compass Therapeutics Presents Novel Biomarker Data Related - GlobeNewswire
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M - Simply Wall St
Treatment Resistant Depression Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Treatment Resistant Depression Pipeline Therapeutics, - openPR
Compass delays anticipated psilocybin readout, cuts staff - Yahoo Finance
Kidney Compass: Semaglutide for Nondiabetic Kidney Disease, with Hiddo Heerspink, PhD, PharmD, at Kidney Week 2024 - MD Magazine
Treatment Resistant Depression Clinical Trials 2024: FDA - openPR
Biotech stock tumbles after unexplained 1,446% gain - MSN
Cholangiocarcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Can you now get a good deal on Compass Therapeutics Inc’s shares? - US Post News
Financial Snapshot: Analyzing Compass Therapeutics Inc (CMPX)’s Key Ratio Metrics - The Dwinnex
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market - Investing News Network
CMPX’s 2023 Market Dance: Up 26.92% – Time to Invest? - The InvestChronicle
Renaissance Technologies LLC Decreases Position in Imperial Petroleum Inc. (NASDAQ:IMPP) - Defense World
JetBlue Airways (NASDAQ:JBLU) Raised to “Sell” at StockNews.com - Defense World
Cholangiocarcinoma Clinical Trials 2024: EMA, PDMA, FDA - openPR
Silicon Laboratories Inc. (NASDAQ:SLAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - ForexTV.com
Compass Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire
Compass Therapeutics Inc (CMPX)’s stock price range in the last year - US Post News
American Century Companies Inc. Cuts Stake in Compass Minerals International, Inc. (NYSE:CMP) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 23.7% in September - MarketBeat
Rhumbline Advisers Takes Position in LINKBANCORP, Inc. (NASDAQ:LNKB) - Defense World
Rhumbline Advisers Trims Holdings in Pembina Pipeline Co. (NYSE:PBA) - Defense World
Analyzing Neurocrine Biosciences (NASDAQ:NBIX) and Compass Therapeutics (NASDAQ:CMPX) - Defense World
NSK (OTCMKTS:NPSKY) Stock Price Passes Above 50-Day Moving Average of $10.02 - Defense World
PCM Fund Inc. (NYSE:PCM) Short Interest Down 36.3% in September - Defense World
Federated Hermes Inc. Has $51,000 Holdings in Deluxe Co. (NYSE:DLX) - Defense World
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):